Northwestern Researchers Trial New Device that May Support Improved Newborn Health
STAN™ is fetal heart rate monitoring system that measures and tracks the electrical activity of the baby’s heart via an internal electrode, along with uterine contractions and how well the baby uses oxygen during labor. It then interprets the data and signals clinicians when a significant change in oxygen levels or heart rate occurs. The monitor is approved by the Food and Drug Administration and is routinely used in Europe, but has not been widely adopted in the United States yet. At present, it is only available for patients enrolled in the study. If this study demonstrates improved outcomes, it is likely that the monitoring system will become more widely available to mothers giving birth in this country.
“Current monitors measure heart rate alone, relying on the experience and judgment of the clinical team to interpret changes in data,” said Peaceman. “This system captures additional measurements and interprets that data, which may eliminate the guesswork and offer a more accurate assessment of how well the baby is using oxygen.”
Northwestern is one of 14 centers in the United States participating in the clinical trial, which researchers hope will enroll 11,000 women from across the country over the next three years. Subjects who opt to participate in this research study are randomly assigned to one of two groups. One will receive the standard fetal monitoring offered today, and the other will be monitored using the new system in addition to the existing method. The way in which fetal heart rate is monitored will be the only change to the labor and delivery experience, which will continue to be managed by the woman’s doctor. For more information about the STAN clinical trial or to enroll, call 312-926-2475.
Read the full story online. Review recent coverage in the Chicago Tribune.*